Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Huntington Disease

Huntington Disease — NIH Grants & Funding

Active and recent NIH-funded research on Huntington Disease. Data from NIH RePORTER, last 36 months.

MONDO:0007739

NIH-funded research on Huntington Disease

active grants

institutions

researchers

new in last 12 mo.

$101.1M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(52)

Basic ScienceR35Active

Molecular Mechanisms of Pathogenesis in Huntington’s disease

Thompson, Leslie·UNIVERSITY OF CALIFORNIA-IRVINE·IRVINE, CA

$1,172,286 (FY2025)

Huntington Disease — NIH Grants & Funding

Basic Science(52)

Molecular Mechanisms of Pathogenesis in Huntington’s disease

Genetic Mechanisms Controlling Resilience to Huntington's Disease

Interneurons as Early Drivers of Huntington´s Disease Progression

Characterizing the Conformations and Neurotoxic Species of Huntingtin

Regulation of HTT-mediated DNA damage repair and chromatin remodeling Complexes

Understanding the Contribution of Altered Cerebrovascular Function to the Pathology and Clinical Symptoms of Huntington Disease

Dissecting the role of DNA Ligase 1 in Huntington's disease

Cerebrospinal fluid dynamics in Huntington's disease

Huntington's Disease Repeat Instability and Pathogenesis

Huntingtin links inflammasome pathway in Huntington's disease Pathogenesis

Translational(15)

Modeling Huntingtons disease in iPSC-derived astrocytes

Uncovering the molecular target(s) of ORI-113, a potential brain-penetrant small molecule therapeutic for Huntington's disease.

In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease

Understanding small molecule modulation of splicing for Huntington's disease therapy

Therapeutic targeting of DNA methyltransferases in Huntington's disease

Validation of Novel Pathogenic Post-Translational Modifications of Huntingtin, and of Modifying Enzymes as Therapeutic Targets for Huntington's Disease

Validating cGAS-STING pathway as drug target in Huntington disease mouse model

Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease

Determining Selective Autophagy Kinase in Modulating Neurotoxicity in Huntington's Disease Model

Understanding the Relationship Between Protein Homeostasis and Sleep Dysfunction in Mouse Models of Huntington's Disease

Clinical(8)

Growth and development of Striatal-Cerebellum circuitry in subjects at risk for Huntington’s Disease

Measuring Digital Clinical Endpoints in Huntington's Disease (MEND-HD)

Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression

Longitudinal Assessment of Brain Structure and Function in Juvenile Onset Huntington's Disease

Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders

Correlating molecular behavioral phenotypes in a marmoset model of Huntingtons disease

Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington disease

Investigating Autonomic Dysfunction as an Early Pathologic Feature of Huntington’s Disease

Epi / Nat. History(2)

Preparing for preventive clinical trials in Huntington's disease

Environmental drivers of trinucleotide repeat instability and Huntington's disease onset

Gene/Cell Therapy(4)

Therapeutic Potential of Base Editing Strategies to Convert CAG to CAA in Huntington's Disease

Admin. Supp.: Correction of Neurological Disease via Allele Specific Excision of Pathogenic Repeats

Advancing RNA Therapeutics for Huntington’s Disease

Epigenetic Pathology and Therapy in Huntington's Disease

Biomarker / Dx(4)

Genetically Encoded Probes of Huntingtin Misfolding

Developing novel nanobody-based biosensors and therapeutics for Huntington’s Disease

COX-2-Selective PET Imaging as an Onset Marker of Huntington's Disease

Decoding cerebrospinal fluid huntingtin biomarkers

Medical Device(1)

A Wearable Sensor Platform for Remote Monitoring of Motor Impairment in Huntingtons Disease and Prodromal Huntingtons Disease

Other(4)

Identifying Factors Regulating Medium Spiny Neuron Differentiation or Maintenance as Therapeutic Targets for Huntington's Disease using Induced Pluripotent Stem Cells

Molecular mechanisms of synaptic dysfunction and cognitive decline in Huntington's disease

Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat Disorders

MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE